Medtronic (MDT): In-Line Quarter, Raising PT - Piper Jaffray

Go back to Medtronic (MDT): In-Line Quarter, Raising PT - Piper Jaffray

Wedbush Raises Price Target on Medtronic (MDT) to $82 Following 4Q Report

June 1, 2016 8:41 AM EDT

Wedbush reiterated a Neutral rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $82.00 (from $79.00), following the company's 4Q earnings report. MDT reported revenue of $7,567 million, beating the consensus revenue estimate of $7,479 million and was above the upper end of guidance at... More

Leerink Partners Raises Price Target on Medtronic (MDT) Following 4Q Report

June 1, 2016 7:49 AM EDT

Leerink Partners reiterated a Market Perform rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $85.00 (from $82.00), following the company's 4Q earnings report. MDT delivered its 6th consecutive quarter of mid- to high-single-digit sales growth, building a consistent track record.

Analyst Danielle Antalffy commented, "MDT shares traded lower yesterday driven by what we believe were expectations of more positive operating leverage than the company delivered, potentially as well as a more... More

Medtronic (MDT) Tops Q4 EPS by 1c

May 31, 2016 6:47 AM EDT

Medtronic (NYSE: MDT) reported Q4 EPS of $1.27, $0.01 better than the analyst estimate of $1.26. Revenue for the quarter came in at $7.57 billion versus the consensus estimate of $7.49 billion.

GUIDANCE:

Medtronic sees FY2017 EPS of $4.60-$4.70, versus the consensus of $4.70.

In fiscal... More